Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNovoCure Limited Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 5 | -$0.55 | -$0.37 | -$0.46 |
| Q2 2025 | 7 | -$0.45 | -$0.36 | -$0.38 |
| Q3 2025 | 6 | -$0.47 | -$0.38 | -$0.42 |
| Q4 2025 | 5 | -$0.51 | -$0.32 | -$0.40 |
| Q1 2026 | 4 | -$0.41 | -$0.34 | -$0.37 |
| Q2 2026 | 1 | -$0.38 | -$0.33 | -$0.36 |
| Q3 2026 | 1 | -$0.37 | -$0.32 | -$0.35 |
| Q4 2026 | 1 | -$0.36 | -$0.32 | -$0.34 |
| Q1 2027 | 1 | -$0.34 | -$0.30 | -$0.32 |
| Q2 2027 | 1 | -$0.30 | -$0.26 | -$0.28 |
| Q3 2027 | 1 | -$0.24 | -$0.21 | -$0.23 |
| Q4 2027 | 1 | -$0.26 | -$0.23 | -$0.25 |
NovoCure Limited Earnings Date And Information
NovoCure Limited last posted its earnings results on Thursday, October 30th, 2025. The company reported $-0.33 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.09. The company had revenue of 167.20 M for the quarter and had revenue of 605.22 M for the year. NovoCure Limited has generated $-2 earnings per share over the last year ($-1.56 diluted earnings per share) and currently has a price-to-earnings ratio of -7.63. NovoCure Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 19th, 2026 based on prior year's report dates.
NovoCure Limited Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2025 | Q3 2025 | -$0.42 | -$0.33 | 0.09 | $158.94 M | $167.20 M |
| 07/24/2025 | Q2 2025 | -$0.39 | -$0.36 | 0.03 | $154.16 M | $158.81 M |
| 04/24/2025 | Q1 2025 | -$0.47 | -$0.31 | 0.16 | N/A | $154.99 M |
| 02/27/2025 | Q4 2024 | -$0.34 | -$0.61 | -0.27 | N/A | $161.27 M |
| 10/30/2024 | Q3 2024 | -$0.34 | -$0.28 | 0.06 | $143.95 M | $155.10 M |
| 07/25/2024 | Q2 2024 | -$0.40 | -$0.31 | 0.09 | $135.83 M | $150.36 M |
| 05/02/2024 | Q1 2024 | -$0.43 | -$0.36 | 0.07 | N/A | $138.50 M |
| 02/22/2024 | Q4 2023 | -$0.53 | -$0.44 | 0.09 | N/A | $133.78 M |
| 10/26/2023 | Q3 2023 | -$0.52 | -$0.46 | 0.06 | $128.75 M | $127.32 M |
| 07/27/2023 | Q2 2023 | -$0.50 | -$0.54 | -0.04 | $124.25 M | $126.05 M |
| 05/04/2023 | Q1 2023 | -$0.36 | -$0.50 | -0.14 | $127.77 M | $122.18 M |
| 02/23/2023 | Q4 2022 | -$0.32 | -$0.36 | -0.04 | $128.40 M | $128.43 M |
| 10/27/2022 | Q3 2022 | -$0.30 | -$0.25 | 0.05 | $130.61 M | $131.00 M |
| 07/28/2022 | Q2 2022 | -$0.14 | -$0.23 | -0.09 | $134.97 M | $140.87 M |
| 04/28/2022 | Q1 2022 | -$0.17 | -$0.04 | 0.13 | $134.08 M | $137.55 M |
| 02/24/2022 | Q4 2021 | -$0.10 | -$0.25 | -0.15 | $133.00 M | $133.21 M |
| 10/28/2021 | Q3 2021 | -$0.06 | -$0.13 | -0.07 | $141.27 M | $133.61 M |
| 07/29/2021 | Q2 2021 | -$0.01 | -$0.14 | -0.13 | $141.50 M | $133.52 M |
| 04/29/2021 | Q1 2021 | -$0.01 | -$0.04 | -0.03 | $138.70 M | $134.70 M |
| 02/25/2021 | Q4 2020 | $0.12 | $0.05 | -0.07 | $144.00 M | $143.95 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
NovoCure Limited Earnings: FAQ's
NovoCure Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 19th, 2026 based offlast year's report dates.
In the previous quarter, NovoCure Limited (:NVCR) reported $-0.33 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.09.
The conference call for NovoCure Limited's latest earnings report can be listened to online.
The conference call transcript for NovoCure Limited's latest earnings report can be read online.
NovoCure Limited (:NVCR) has a recorded annual revenue of $605.22 M.
NovoCure Limited (:NVCR) has a recorded net income of $-168,627,000.NovoCure Limited has generated $-1.56 earnings per share over the last four quarters.
NovoCure Limited (:NVCR) has a price-to-earnings ratio of -7.63 and price/earnings-to-growth ratio is 2.38.